CD274 and non-small cell lung carcinoma: The results of the CheckMate-059 trial showed that patients with advanced NSCLC, which progressed on platinum-based therapies achieved a significantly higher overall survival when treated with nivolumab, an anti-PD-L1 therapy (1 yr OS: 51% [Nivolumab] vs 39% [Docetaxel], with median survival 12.2 months vs 9.4 months [p=0.002]) [53].